Predictors of competing mortality in advanced head and neck cancer. - Test2 - elhamkhani - TriplyDB

Predictors of competing mortality in advanced head and neck cancer.

Predictors of competing mortality in advanced head and neck cancer.

http://www.wikidata.org/entity/Q46215317

about

Recent advancements in multimodality treatment of gliomas EMT, CTCs and CSCs in tumor relapse and drug-resistance A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study)Causes of death in long-term survivors of head and neck cancer.[Translational research in head and neck cancer. Biological characteristics and general aspects].Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.Predictors of competing mortality to invasive breast cancer incidence in the Canadian National Breast Screening study.The combined effect of individual and neighborhood socioeconomic status on cancer survival rates Impact of age on the cancer-specific survival of patients with localized renal cell carcinoma: martingale residual and competing risks analysis Antibody-based therapeutics to watch in 2011.Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types Biology and management of clear cell sarcoma: state of the art and future perspectives.Elderly patients with squamous cell carcinoma of the head and neck and the benefit of multimodality therapy.Pharmacokinetic evaluation of fosaprepitant dimeglumine Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.How do Malawian women rate the quality of maternal and newborn care? Experiences and perceptions of women in the central and southern regions Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States.Personalized therapy in endometrial cancer: challenges and opportunities.Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism Competing causes of death in patients with oropharyngeal cancer treated with radiotherapy.Pretreatment dietary patterns, weight status, and head and neck squamous cell carcinoma prognosis Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.Noncancer-Related Health Events and Mortality in Head and Neck Cancer Patients After Definitive Radiotherapy: A Prospective Study Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab Randomized clinical trial on 7-days-a-week post-operative radiotherapy vs concurrent post-operative radiochemotherapy in locally advanced cancer of the oral cavity/oropharynx: a report on acute normal tissue reactions.Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence.Role of comorbidity on outcome of head and neck cancer: a population-based study in Thuringia, Germany.Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients.Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.Review on clinical trials of targeted treatments in malignant mesothelioma.Patterns of care and survival for glioblastoma patients in the Veterans population.The emerging era of personalized therapy in squamous cell carcinoma of the head and neck.Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions.Eribulin mesylate for the treatment of late-stage breast cancer.Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.Emerging drugs for neuroblastoma.

P2860

Q27001724-589EA73E-7729-4B9F-95B1-F33FAD60ADF7 Q28082935-058E77B4-B1A6-4FD3-8ED3-3AC37021383D Q33647636-7F16B31E-B0AC-45FD-AF9B-2BB135CE3B9C Q33913896-8B0D44E1-649B-4F88-82DA-05A9FE4E218F Q34000961-EB3C5252-980C-498C-93F6-DED42449ECD3 Q34098286-6E77ECEC-4144-4F7F-9457-2AFC1060B0E2 Q34343656-87F50727-E773-465D-92C6-A3504283C058 Q34407878-9E0CAE0A-355E-4B01-A423-17B7666EFBFA Q34465177-94EAB06E-DFA4-40BD-9440-C8834FF97997 Q34570079-08A5E719-4C12-4AC2-AFFD-FB99F337EFAE Q34669751-1CA14677-F10C-4601-8751-99C5B2A6A8CA Q34677457-5DC4D583-DBD4-4243-AC9C-7542C5E0A3E5 Q35057282-954CF104-92AC-4B20-BFC8-5188BCA55FC7 Q35163168-F422238F-F5FD-4097-8B12-FC79F2D29D4C Q35418808-81FC7528-C9D2-45FC-BCD7-FC5F4592C63B Q35551059-2D45BE93-F241-4F0F-8D43-6863F18B7B07 Q35746825-C5973AEC-C4C0-429B-8050-148302022A59 Q35858280-5FDFBFF5-FC34-41F5-9BDA-3590291CCF35 Q35911350-6F0128D1-57BA-41FC-9254-6FEEFDD2CA37 Q35925651-D0207826-4F73-43AD-8BDB-79A8C0B0CEAF Q36092931-A4BB6C23-446A-48B2-A489-28578C8F00B2 Q36224590-2ECCE95B-D062-4FC0-A971-129FFDF9392E Q36534870-DE1CF93D-98B9-4D1F-8100-C7F2024B39F0 Q36844285-1137D2BE-CBCF-4405-B37D-ACD80C54271E Q36993334-BE127685-DA2C-41E9-80BB-9123DE64D13D Q37146157-30AE88D8-01BA-47B0-A1A8-8ED1DE883F10 Q37176459-3BC68220-B88E-4510-B85A-59331B1FCA2B Q37276259-C3F34D9E-01F8-487B-A309-12F1E0980058 Q37429990-8809BD8B-3133-4FD5-9E4C-F6C4463F519C Q37601809-D3A2F0B3-9D3A-406F-9E2D-944E287C28FF Q37692445-07577049-CF54-4DE1-B2CE-042E327EB056 Q37873380-F9308C0E-1063-4EC6-90FC-47ECCB90D23D Q37924635-81AA5B4D-285B-4477-9FFC-E800307B8AF0 Q37925133-00908403-B48D-48C9-A536-5559B46A71AA Q37930893-83F244BC-976D-4AE3-B79A-069BDB69CDE8 Q37956659-151C22D1-F5DF-4000-AEE5-ED94D3234A56 Q38020245-0A84CC2C-10EB-45E6-8AC5-24EA7866FEA6 Q38073827-2DD010FF-9018-4A64-9981-D347A0460FBC Q38101590-F43F3DA2-642E-4DA1-9C64-EB2C37E8407E Q38108399-5D45E65C-851B-4FB2-A72A-2248C8EE0AE4

P2860

Predictors of competing mortality in advanced head and neck cancer.

http://www.wikidata.org/entity/Q46215317

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Predictors of competing mortality in advanced head and neck cancer.

@en

Predictors of competing mortality in advanced head and neck cancer.

@nl

type

label

Predictors of competing mortality in advanced head and neck cancer.

@en

Predictors of competing mortality in advanced head and neck cancer.

@nl

prefLabel

Predictors of competing mortality in advanced head and neck cancer.

@en

Predictors of competing mortality in advanced head and neck cancer.

@nl

P1433

Q46215317-CA71A62C-B617-4D7B-A9FD-8FC671AE9993

P1476

Q46215317-6799740E-7862-4C26-BB16-4F7D7F3C4E83

P2093

Q46215317-3A4D6A41-5964-40F1-8879-C4FF7CBAFFE3

Q46215317-3FB800F0-FFB6-42FE-8169-7F45C67F5928

Q46215317-5448F6A9-5A55-43BB-8E03-258FECD9F37D

Q46215317-6008E748-F225-47EF-9D6F-D6E6AD079E99

Q46215317-6E0591D8-664E-4587-A3FB-54CC228E976E

Q46215317-76B43DB7-66DB-4B7D-9249-C9FBBDAF04FF

Q46215317-9FB1DB8D-E278-483E-9D03-A9875871657F

Q46215317-CD030010-1430-44D7-82BC-DB9324264797

Q46215317-E2CFDA6E-C76B-4B34-AA1C-688857BF6700

P304

Q46215317-000B4873-7581-4C6C-97F1-66D509650003

P31

Q46215317-70344285-B74A-4FD2-9526-781E302B9C3D

P356

Q46215317-6E010E76-22BE-4A37-B138-D71BF02A2DA2

P407

Q46215317-59DDECFC-8E75-41DF-A94C-6529BA10810A

P433

Q46215317-D5A1B6D9-3652-4624-9594-1041F147C7EE

P478

Q46215317-07B5E954-49EF-41A0-94CA-85A58F9880D2

P50

Q46215317-09992D38-D755-42B8-9166-DA1707520A88

Q46215317-7E8F6D84-C082-42DC-AB1F-1A3F0BBF5338

Q46215317-89D6335F-409B-4713-931F-D4EA6CA59D01

P577

Q46215317-A2CBB366-4A10-444F-A19B-588BF3EC7185

P698

Q46215317-718D1C7B-70B0-4D06-8307-8E94B63DA41B

P356

JCO.2008.20.9288

P1433

Journal of Clinical Oncology

P1476

Predictors of competing mortality in advanced head and neck cancer.

@en

P2093

Amit D Bhate

http://www.w3.org/2001/XMLSchema#string

Bharat B Mittal

http://www.w3.org/2001/XMLSchema#string

Blase N Polite

http://www.w3.org/2001/XMLSchema#string

Daniel J Haraf

http://www.w3.org/2001/XMLSchema#string

Ezra E W Cohen

http://www.w3.org/2001/XMLSchema#string

James J Dignam

http://www.w3.org/2001/XMLSchema#string

Joseph K Salama

http://www.w3.org/2001/XMLSchema#string

Mary Ellyn Witt

http://www.w3.org/2001/XMLSchema#string

Virag Dandekar

http://www.w3.org/2001/XMLSchema#string

P304

15-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.9288

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Ralph Weichselbaum

Everett E Vokes

P577

2009-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19933920

http://www.w3.org/2001/XMLSchema#string